AU2022238386A1 - Methods of administering long-acting growth hormone polypeptides - Google Patents

Methods of administering long-acting growth hormone polypeptides Download PDF

Info

Publication number
AU2022238386A1
AU2022238386A1 AU2022238386A AU2022238386A AU2022238386A1 AU 2022238386 A1 AU2022238386 A1 AU 2022238386A1 AU 2022238386 A AU2022238386 A AU 2022238386A AU 2022238386 A AU2022238386 A AU 2022238386A AU 2022238386 A1 AU2022238386 A1 AU 2022238386A1
Authority
AU
Australia
Prior art keywords
subject
long
rhgh
dose level
week
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022238386A
Other languages
English (en)
Inventor
Jóse Francisco CARA
Aleksandra Pastrak
Srinivas Rao VALLURI
Michael Paul WAJNRAJCH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opko Biologics Ltd
Pfizer Inc
Original Assignee
Opko Biologics Ltd
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Biologics Ltd, Pfizer Inc filed Critical Opko Biologics Ltd
Publication of AU2022238386A1 publication Critical patent/AU2022238386A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2022238386A 2021-03-19 2022-03-17 Methods of administering long-acting growth hormone polypeptides Pending AU2022238386A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163163504P 2021-03-19 2021-03-19
US63/163,504 2021-03-19
US202163272417P 2021-10-27 2021-10-27
US63/272,417 2021-10-27
PCT/US2022/020804 WO2022197961A1 (en) 2021-03-19 2022-03-17 Methods of administering long-acting growth hormone polypeptides

Publications (1)

Publication Number Publication Date
AU2022238386A1 true AU2022238386A1 (en) 2023-09-14

Family

ID=83320806

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022238386A Pending AU2022238386A1 (en) 2021-03-19 2022-03-17 Methods of administering long-acting growth hormone polypeptides

Country Status (10)

Country Link
US (1) US20240166710A1 (https=)
EP (1) EP4308151A4 (https=)
JP (1) JP2022145646A (https=)
KR (1) KR20230171936A (https=)
AU (1) AU2022238386A1 (https=)
BR (1) BR112023018980A2 (https=)
CA (1) CA3214273A1 (https=)
IL (1) IL305661A (https=)
MX (1) MX2023010997A (https=)
WO (1) WO2022197961A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020155990A1 (en) * 2001-04-20 2002-10-24 Renasci, Inc., D/B/A Renasci Anti-Aging Center Method of optimizing growth hormone replacement
WO2009102734A1 (en) * 2008-02-11 2009-08-20 Depomed Inc. Methods for treating vasomotor symptoms using gaba analogs in a gastric retentive dosage form
US20150158926A1 (en) * 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
RU2746943C2 (ru) * 2013-10-21 2021-04-22 Опко Байолоджикс Лтд. Полипептиды длительного действия и способы их получения и введения
DK3220892T3 (da) * 2014-11-21 2021-11-08 Ascendis Pharma Endocrinology Div A/S Langtidsvirkende væksthormondoseringsformer
HRP20230405T8 (hr) * 2014-12-10 2023-09-29 Opko Biologics Ltd. Metode proizvodnje dugo djelujućih ctp-modificiranih polipeptida hormona rasta
JP7000153B2 (ja) * 2014-12-10 2022-01-19 オプコ バイオロジクス リミテッド 長時間作用性ｃｔｐ修飾成長ホルモンポリペプチドを生成する方法

Also Published As

Publication number Publication date
CA3214273A1 (en) 2022-09-22
MX2023010997A (es) 2023-11-28
JP2022145646A (ja) 2022-10-04
EP4308151A1 (en) 2024-01-24
WO2022197961A1 (en) 2022-09-22
BR112023018980A2 (pt) 2023-12-05
US20240166710A1 (en) 2024-05-23
IL305661A (en) 2023-11-01
EP4308151A4 (en) 2025-02-26
KR20230171936A (ko) 2023-12-21

Similar Documents

Publication Publication Date Title
Gharib et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children—2003 update
US20160310576A1 (en) Long-acting polypeptides and methods of producing and administering same
JP2017125051A (ja) Ｈｇｈ−ｘｔｅｎ融合タンパク質および成長ホルモン欠乏症の処置におけるその使用
Smith et al. A growth differentiation factor 15 receptor agonist in randomized placebo-controlled trials in healthy or obese persons
US20140162954A1 (en) Fusion of human growth hormone and albumin formulation and uses thereof
US20160271265A1 (en) Insulin-like growth factor mimetics for use in therapy
TWI777407B (zh) 長效型多肽及其生產和給藥的方法
US20240166710A1 (en) Methods of administering long-acting growth hormone polypeptides
CN117425490A (zh) 施用长效生长激素多肽的方法
Kemp Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options
Roelfsema et al. Nanomedicines in the treatment of acromegaly: focus on pegvisomant
HK40098775A (zh) 施用长效生长激素多肽的方法
Hasegawa et al. Current understanding and perspectives on growth and long-acting GH therapy in Japan
Dao et al. Human growth hormone
Çetinkaya et al. Long-acting growth hormone therapy, rational and future aspects
Yuen et al. Long-acting Growth Hormone Preparations
US20070066519A1 (en) Use of human growth hormone in multiple system atrophy
Wang et al. Tesamorelin, a human growth hormone releasing factor analogue
Dao et al. Human growth hormone
US20250325560A1 (en) Methods for improving muscle mass, strength, or function with a combination of testosterone and growth hormone
Luz et al. History and Current Status of Growth Hormone Treatment in Children: CC Luz, PF Collett-Solberg
US20200000884A1 (en) Treatment of adult growth hormone deficiency with human growth hormone analogues
Steelman et al. Cara, CL Roland, CT Taylor, SR Valluri, and MP Wajnrajch are employees
Class et al. Patent application title: FUSION OF HUMAN GROWTH HORMONE AND ALBUMIN FORMULATION AND USES THEREOF Inventors: Kurt Brown (Narbeth, PA, US) Merav Bassan (Netanya, IL) Assignees: Teva Pharmaceutical Industries Ltd.
Ying et al. Once-Weekly Lonapegsomatropin Was Efficacious and Well Tolerated in Chinese Children with Growth Hormone Deficiency: Results from a Phase 3 Randomized Trial